Hospital of Saint Raphael

1450 Chapel Street New Haven, Connecticut 06511



December 7, 1994

USNRC Washington, DC 20555

DOCKET NO. 030-01238 LICENSE NO. 06-00200-03 SUBJECT: REPLY TO NOTICE OF VIOLATION

Dear Sir:


This letter is in reply to a notice of violation resulting from NRC routine inspection No. 030-01238/94-001, conducted by Mr. Ihor Czerwinskyj of the Region I office on October 24 and 25of this year at The Hospital of Saint Raphael in New Haven, CT. We have chosen to respond to the individual violations in the same order as they were presented in, Appendix A, Notice of Violation (attached).

A. Violation: As of October 25, the Quality Management Program (QMP) did not include a written procedure for the use of Strontium-90 as a sealed source in an applicator for treatment of superficial eye conditions.

Reply: Revisions to the Quality Management Program were submitted to the Region I Quality Management Program Coordinator in November of 1994. Included among the revisions was a separate Written Directive Worksheet for the use of the Strontium-90 Eye Applicator (see attached). Acknowledgement of the revised QMP was received from the Region I QMP coordinator on November 24, 1994. All uses of the Strontium-90 Eye Applicator from 11/24/94 onward require the utilization of the Written Directive Worksheet, which is in accord with Regulatory Guide 8.33, QualityManagement Program.

B. Violation: On July 8, 1993, a survey for removable contamination was not done before assigning another patient to Room 4594 of the Celentano patient wing. This room was the room of a patient who had received radiopharmaceutical therapy and had been hospitalized for compliance with 10CFR 35.75.

Reply: Established written procedures for hospitalized patients who receive I-131 therapy require that a decontamination survey of the room be performed by the RSO prior to the room being released for other uses. On the date in question, the RSO was on vacation and the radiation safety procedures attendent to the I-131 patient were performed by the authorized user. A survey of the I-131 treatment log and the patient's Gart confirmed that there was no record of a decontamination survey. The authorized user is very experienced in the radiation safety procedures required for I-131 patients. One possible reason for the omission of the survey could be that the I-131 treatment log did not contain a specific section for the entry of the results of the decontamination survey. The entries had been made by the RSO by writing a note in the lower right corner of the treatment log. Thus, during the treatment of the patient in question, there was no visual reminder to the authorized user that a survey needed to be done. The I-131 treatment log has been revised (see attached) to include a section which queries the individual responsible for completing the log as to whether the required decontamination survey has



IEON !

Reply to Notice of Violation License No. 06-00200-03 December 7, 1994 Page 2

been done. Time and date of the survey, verification that removable contamination is less than 200 dpm/100 sq cm, and initials of the surveyor are required. Verification of the contamination level will be performed with instrumentation (3" Well Crystal with Multichannel Analyzer) capable of detecting 200 dpm/100sq cm of I-131 contamination. Swipe tests will be done on areas deemed most likely to contain contamination. This revised procedure will go into effect as of 12/7/94.

C. Violation: On November 18, 1993, Cs-137 brachytherapy sources were implanted into a patient who was hospitalized without the performance of a survey of the dose rates in restricted and unrestricted areas contiguous to the room of the implanted patient.

Reply: Established procedures call for a survey of restricted and unrestricted areas following implantation of Cs-137 sealed sources. The logsheet for these procedures contained a section for logging the dose rates at selected points in and around the room. The authorized user who implanted the sources could not verify whether or not a survey was performed. Since procedures detailing the need to perform a survey already exist, it will be necessary for a second individual (either a medical dosimetrist or a radiation physicist) to accompany the authorized user to the patient's room to perform the survey. A separate radiation survey form has been devised (see attached) to contain a scaled drawing of the room utilized for brachytherapy implants. The form has specific locations where exposure rate measurements must be taken and recorded. Upon return to the Radiation Therapy Department, the individual responsible for the survey will submit the survey logsheet to the RSO for review. The RSO will initial the survey logsheet and record the date and time of review. This procedure will insure that a survey will be performed on every brachytherapy implant patient. This procedure is in place as of 12/7/94.

Sincerely,

Michael T. Koff

Director, Ancillary Services

c: Regional Administrator,

Region I USNRC

Brachytherapy Quality Management Program Written Directive Worksheet For Use of Strontium-90 Eye Applicator

Written Directive:
Planned Date of Application: Name of Patient: Treatment Site: Radioisotope:
Source Activity (mCi): Source Output (rads/sec): Treatment Time (seconds): Treatment Dose (rads): Authorized User Signature:
Date:
Warning To Individuals Carrying Out Written Directive:
If any confusion exists as to how to carry out the written directive, you are required to consult with the authorized user who completed the written directive prior to continuing the procedure.
Verification of Patient Identification:
Verification of patient ID accomplished by asking the patient his/her name and one of the following: (circle one)
birth date address ss# checked ID bracelet
Verification of Administration/ Agreement With Written Directive
Date of Administration: Time of Administration: Treatment Site: Radioisotope used: Source Activity (mCi): Source output (rads/sec): Treatment Time (seconds): Treatment Dose (rads):
Was administration in accordance with the written directive? Authorized user signature: Date/Time:

I-131 Therapy Record

Patient Name:	Physician Name:
Date of Administration:	Patient Room #:
Manufacturer's Lot Number(s):	
Manufacturer's Assay:	Date/Time of Assay:
HSR Assay: Date,	/Time of Assay:
Date/Time of Administration of	Isotope:
Written Directive checked prior	to administration to patient?:
Residual vial assay results:	
Activity administered to patient	t:
Initials of individual administe	
Date/Time of Radiation Exposure	Survey:
Survey form placed ino patient's	s therapy chart?:
Initials of individual performing	ng survey:
Measurement of Residual Activity	y Within Patient:
Date: Time: mr/hr @ 1 meter: Residual actvity Initials:	
Date/Time of discharge of Patier Exposure rate at 1 meter from pa Estimated residual activity in particular of individual making me	atient at discharge:patient at discharge:
Decontamination Survey of Patier	nt Room:
Time/Date of survey: Does survey show removeable cont Has all contaminated waste been Initials of individual releasing	placed in storage for decay?:

Hospital of Saint Raphael Area Radiation Survey Diagram Celentano Room 4581

R	50m 4582	Room 4581	6	Room 4580
Patient Name: Date: Radioisotope: Total mCi or	Time:mg-Ra-equiv:			
Site # 1 2 3 4 5 6 7	Location Bedside 3 ft Away 3 ft Away Inner Doorway Outer Doorway Room 4582 Room 4580		Rate mR/hr	Survey Meter Used Manufacturer: Model No.: Serial No.:
8 Survey Perf	Room 4580			

Hospital of Saint Raphael Area Radiation Survey Diagram Celentano Room 4594

